Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Science in Sport FY underlying earnings more than double

(Sharecast News) - Sports nutrition business Science in Sport said on Monday that FY underlying earnings had more than doubled, stating it was "proud" of its performance but noted it had been "challenging" given the level of turnaround required. Science in Sport said FY24 underlying earnings had surged 112.7% to £4.2m, with EBITDA margins improving by five basis points to 8.2% and losses per share improving from 6.6p in FY23 to 2.3p in FY24. Trading contributions increased 7.3% to £13.8m

However, revenues were down 17.2% at £51.9m and gross profits fell 12.5% to £23.5m but noted that it was "confident" of the resetting of its operating model and stepping away from uncommercial revenue streams to provide a platform for accretive growth moving forward.

Looking ahead, Science in Sport said it was taking an "ambitious yet balanced view" on prospects for FY25, where trading performance has "started well" with the improvements made throughout FY24 continuing to annualise.

"The strategic focus areas are driving profitable revenue growth through distribution agreements both domestically and internationally; controlled growth over the medium term supported by effective marketing with a clear strong commercial execution; and, continued margin improvements from ongoing cost challenge resulting in cash generation and deleveraging," said Science in Sport.

"Whilst these improvements have started to be realised maximising the group's full potential is likely to require further capital investment in distribution and product range to scale quickly as significant growth of marginally accretive revenue requires a longer-term outlook."

As of 1005 BST, Science in Sport shares were up 0.77% at 1,080.25p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.